alpha medical semaglutide FDA Warns on Certain Forms of Compounded Benefits of GLP-1 Microdosing GLP-1

doi: 10.3389/fnins.2020.601193

Gastrointestinal Effects The most commonly reported adverse effects are gastrointestinal in nature, including: Nausea and vomiting (affecting 20-40% of patients initially, varying by agent and dose) [8] Diarrhoea or constipation Abdominal discomfort and bloating Reduced appetite In elderly patients, persistent nausea and vomiting can lead to dehydration and electrolyte imbalances more rapidly than in younger adults

Plus, it mimics the other effects of GLP-1 that lead to decreased appetite and subsequent reduced energy intake and weight loss

High), non-diabetic individuals treated with semaglutide (Class IVIII

However, an unfavorable donordonor interaction occurred with DA D:721, which slightly weakened the overall binding efficiency